Business Standard

Emami stock's outperformance to continue

In September, 2012, Emami recorded strong growth of 16%

Related News

stock outperformed in last three months, with the scrip gaining 29.3 per cent compared to a 9.5 percent gain of the index. The last one month has also seen the stock gaining 22.6 percent as compared to the index which was marginally down.

This is mainly due to strong sales performance reported by the company in past several quarters backed by robust volume growth.

In September 2012 quarter, where many peers have struggled in reporting robust volume growth, Emami recorded of 16 per cent thus resulting in strong growth of 22 per cent in domestic sales (95 per cent of total revenues).

Earlier the company’s revenue model was predominantly driven by seasonal nature of its products (read winter products) and hence second half of the fiscal was usually better than the first half thanks to the busy period. However the seasonality factor has reduced for the company now with growing international business and rising share of products like talcum powder, balm, Navratna cooling oil, fair and handsome. The company is doing well in these new focus areas and growth in domestic market including rural areas remain strong. However, international business continues to be a worry. The company is hopeful of good growth over the next couple of quarters.


In a bid to report high sales growth, margins have suffered and may continue to remain under pressure going ahead due to continued high costs on account of recruitment of senior people in international business division and research and development, capacity expansion (Egypt, India), continued higher menthol prices (till high priced contracts expires, benefit of low prices likely to be visible after March 2013 quarter) and continued focus on advertising and promotions.

But analysts do not see it as a major concern  as long as demand  (read volume growth) outlook is strong (which is the case with Emami) that has become critical for FMCG players and many are not able to live upto expectations. They maintain their buy recommendation on the stock, which trade at 28 times FY13 estimated valuations.

Emami stock outperformed BSE FMCG index in last three months, with the scrip gaining 29.3 per cent compared to a 9.5 percent gain of the index. The last one month has also seen the stock gaining 22.6 percent as compared to the index which was marginally down.

 

Read more on:   
|
|

Emami stock's outperformance to continue

In September, 2012, Emami recorded strong growth of 16%

Emami stock outperformed BSE FMCG index in last three months, with the scrip gaining 29.3 per cent compared to a 9.5 percent gain of the index. The last one month has also seen the stock gaining 22.6 percent as compared to the index which was marginally down.

stock outperformed in last three months, with the scrip gaining 29.3 per cent compared to a 9.5 percent gain of the index. The last one month has also seen the stock gaining 22.6 percent as compared to the index which was marginally down.

This is mainly due to strong sales performance reported by the company in past several quarters backed by robust volume growth.

In September 2012 quarter, where many peers have struggled in reporting robust volume growth, Emami recorded of 16 per cent thus resulting in strong growth of 22 per cent in domestic sales (95 per cent of total revenues).

Earlier the company’s revenue model was predominantly driven by seasonal nature of its products (read winter products) and hence second half of the fiscal was usually better than the first half thanks to the busy period. However the seasonality factor has reduced for the company now with growing international business and rising share of products like talcum powder, balm, Navratna cooling oil, fair and handsome. The company is doing well in these new focus areas and growth in domestic market including rural areas remain strong. However, international business continues to be a worry. The company is hopeful of good growth over the next couple of quarters.


In a bid to report high sales growth, margins have suffered and may continue to remain under pressure going ahead due to continued high costs on account of recruitment of senior people in international business division and research and development, capacity expansion (Egypt, India), continued higher menthol prices (till high priced contracts expires, benefit of low prices likely to be visible after March 2013 quarter) and continued focus on advertising and promotions.

But analysts do not see it as a major concern  as long as demand  (read volume growth) outlook is strong (which is the case with Emami) that has become critical for FMCG players and many are not able to live upto expectations. They maintain their buy recommendation on the stock, which trade at 28 times FY13 estimated valuations.

Emami stock outperformed BSE FMCG index in last three months, with the scrip gaining 29.3 per cent compared to a 9.5 percent gain of the index. The last one month has also seen the stock gaining 22.6 percent as compared to the index which was marginally down.

 

image

Read More

BSE launches carbon index

Premier bourse BSE, in collaboration with the UK government, today launched BSE Carbonex, the first-of-its-kind index in India or any emerging market ...

Recommended for you

Quick Links

Market News

Nickel rises by 0.1% on Asian cues

Traders strengthened positions amid a firming Asian cues

Oil prices rise further in Asia

Expectations of a decline in US crude inventories and robust economic data from the eurozone helped prices

Markets remain rangebound; HUL up over 2%, Hindalco dips 1%

Investors are optimistic about a possible solution between Greece and its international creditors to avert a debt crisis

Pharma shares in focus; Aurobindo Pharma hits new high

JB Chemicals, Alembic Pharma, Aurobindo Pharma, Ipca Laboratories and Dishman Pharma were up 3%-11% each.

Infinite Computer gains on board approval for share buyback proposal

The stock spurted 5% at Rs 171 after the board approved the buyback of shares at a maximum price of Rs 220 per share from the open market ...

 

Back to Top